Slide 1: 1Q26 Earnings Presentation
NASDAQ: HBIO 1Q26 Earnings Presentation John Duke, President & CEO Mark Frost, CFO & Treasurer May 12, 2026
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Forward-Looking Statements This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward- looking statements may be identified
Slide 3: First Quarter Operating & Financial Summary
First Quarter Operating & Financial Summary 1Q26 results: Revenue of $20.8, million in line with our guidance Gross margin of 59%, up nearly 300 bps YoY and at the high end of guidance Adjusted EBITDA of $0.8 million, which was flat YoY Actions in the quarter: Increased NPI pipeline sale
Slide 4: 1Q26 Highlights
1Q26 Highlights First quarter results driven by increased pharma & biotech sales Income Statement Components ($ in millions except 1Q26 1Q25 percentages) Revenue 20.8 21.8 Gross Margin 12.2 12.2 % of Revenue 59% 56% Operating Income (Loss) (1.2) (49.7) % of Revenue (5.7%) (228.1%) Adjusted Operating
Slide 5: Revenue Breakdown
Revenue Breakdown HBIO Revenue 1Q26 1Q25 % Var Americas decrease due to NIH funding delays which caused lower Americas $9.7M $10.7M -9% academic and government sales EMEA increase due to strong NPI uptake, with higher sales from EMEA $6.5M $6.0M +7% distribution partners and to pharma customers APAC
Slide 6: 1Q26 Earnings, Cash & Debt
1Q26 Earnings, Cash & Debt $ Million except per share data GAAP ADJUSTED Cash flow from operations decreased primarily due to higher inventory as well as one-time costs related to the reverse split and S3 filing * Non-GAAP measure, see Slides 10-12 for reconciliation to GAAP financial measures 6
Slide 7: Outlook
Outlook 7
Slide 8: Outlook
Outlook REVENUE ADJ. GROSS MARGIN ADJ. EBITDA 2Q26 Revenue between $20.5M - $22.5M 2Q26 GM between 57% - 59% 2Q26 Adj. EBITDA between $1M - $2M FY26 Revenue growth between 2% - 4% FY26 GM between 58% - 60% FY26 Adj. EBITDA growth between 6% - 10% 8
Slide 9: Appendix
Appendix 9
Slide 10: Non-GAAP Reconciliation Table – Adjusted Operating Income
Non-GAAP Reconciliation Table – Adjusted Operating Income (1) Other operating expenses for the three months ended March 31, 2026 includes $235 thousand of restructuring-related charges compared to $93 thousand of restructuring-related charges and $171 thousand of employee retention tax credit fees f
Slide 11: Non-GAAP Reconciliation Table – Adjusted EBITDA
Non-GAAP Reconciliation Table – Adjusted EBITDA (1) Other operating expenses for the three months ended March 31, 2026 includes $235 thousand of restructuring-related charges compared to $93 thousand of restructuring-related charges and $171 thousand of employee retention tax credit fees for the thr
Slide 12: Non-GAAP Reconciliation Tables – Adjusted EPS & Net Debt
Non-GAAP Reconciliation Tables – Adjusted EPS & Net Debt Three Months Ended Three Months Ended 3/31/2026 3/31/2025 Diluted loss per share (GAAP) * $ (0.77) $ (11.42) Diluted adjusted loss per share * $ (0.33) $ (1.25) Weighted average common shares: Diluted GAAP * 4,473 4,410 Diluted Adjusted * 4,47
Slide 13: 13
13